Clinical Trials & CROs

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips has initiated a major international clinical trial to evaluate its new ultra-low X-ray dose technology designed for coronary procedures. The RADIQAL trial aims to generate real-world evidence that the innovation can significantly reduce radiation exposure for both patients and clinical staff without compromising the image quality or procedural performance critical to interventional cardiology.

Strategic push for radiation dose reduction in cardiology

SHERIDAN, WYOMING – July 25, 2025 – Genentech has confirmed another round of workforce reductions at its South San Francisco headquarters, cutting 87 jobs effective September 15, 2025. The move comes as part of a broader, ongoing strategy to recalibrate operations and align resources with evolving scientific and business priorities.

SHERIDAN, WYOMING – July 25, 2025 – AbbVie and ADARx Pharmaceuticals have announced a major strategic collaboration and license option agreement to co-develop next-generation small interfering RNA (siRNA) therapeutics, targeting several high-impact disease areas including neuroscience, immunology and oncology.

SHERIDAN, WYOMING – July 25, 2025 – ADARx Pharmaceuticals is making waves in the RNA therapeutics landscape under the leadership of CEO Zhen Li, who has emerged as a key figure in advancing siRNA technologies with precision, partnership, and purpose. With a $200 million Series C financing round completed and a major strategic licensing deal secured with AbbVie, ADARx is expanding its pipeline while positioning itself for long-term commercial impact.

Forging a Leadership Path from Chemistry to Commercialization

SHERIDAN, WYOMING – July 25, 2025 – AstraZeneca has reported positive topline results from its Phase III PREVAIL trial evaluating gefurulimab, a complement C5-inhibiting nanobody, for the treatment of generalized myasthenia gravis (gMG). The investigational therapy met all primary and secondary endpoints, signaling a potential new contender in the highly competitive $20 billion gMG market.

Phase III Results Suggest Clinical Significance

SHERIDAN, WYOMING – July 25, 2025 – Novartis AG has entered a strategic drug discovery alliance with Matchpoint Therapeutics, securing global rights to novel oral inhibitors aimed at treating multiple inflammatory conditions. The deal underscores Novartis' commitment to expanding its pipeline through innovation-driven partnerships and bolsters its focus on next-generation therapeutic platforms.

Strategic investment in covalent chemistry

SHERIDAN, WYOMING – July 25, 2025 – In a strategic move to deepen its oncology portfolio and join the accelerating global race for antibody-drug conjugates (ADCs), NextCure has announced a major licensing agreement with China's Simcere Pharmaceutical Group, securing ex-China rights to a novel ADC candidate targeting solid tumors.

SHERIDAN, WYOMING – July 25, 2025 – The U.S. Food and Drug Administration has delayed its decision on GSK’s antibody-drug conjugate Blenrep, postponing the company's market reentry plans for the treatment of relapsed or refractory multiple myeloma. The updated Prescription Drug User Fee Act (PDUFA) target date is now set for October 23, 2025, following the agency's request for additional information.

SHERIDAN, WYOMING – July 25, 2025 – Maryland continues to assert itself as a national leader in life sciences, driven by a dynamic workforce, strong academic institutions, and expanding industry infrastructure. With the Washington, D.C.–Baltimore area ranking among the top six U.S. regions for R&D and manufacturing talent, the state is attracting significant investment and fostering sustainable growth across biotech and pharmaceutical sectors.

Talent-Driven Advantage for Life Sciences Expansion

SHERIDAN, WYOMING – July 25, 2025 – Roche has officially discontinued development of CT-173, an investigational PYY analog once positioned as a novel obesity treatment, citing a lack of competitiveness and development potential in its latest strategic assessment.